Kyowa Kirin (KYKOF) Stock Price, News & Analysis

Company Overview

Kyowa Kirin Co., Ltd. is a Japan-based pharmaceutical company that develops and commercializes innovative medicines, with a focus on specialty and rare diseases. Its research activities span oncology, immunology, allergy, nephrology, and other areas where significant unmet medical needs remain. The company uses technologies including antibody engineering and other biopharmaceutical approaches, as well as small-molecule drug development.

Kyowa Kirin’s products include Crysvita (burosumab), a treatment for certain rare disorders involving abnormal phosphate regulation, and Poteligeo (mogamulizumab), an antibody used in the treatment of particular forms of blood cancer. The company also markets additional prescription medicines in Japan and other regions, and maintains a development pipeline focused on rare diseases, cancer, and immune-mediated conditions.

The company traces its history to Kyowa Hakko Kogyo, founded in 1949. Kyowa Hakko Kogyo and Kirin Pharma combined their pharmaceutical operations in 2008, creating Kyowa Hakko Kirin, which adopted the name Kyowa Kirin in 2019. Headquartered in Tokyo, Kyowa Kirin operates through businesses and partnerships in Japan, North America, Europe, and other international markets, and is part of the Kirin Holdings group.

Key Stats

• Today's Range: $14.45 to $14.45
• 50-Day Range: $14.21 to $15.80
• 52-Week Range: $14.31 to $15.90
• Volume: 342 shs
• Average Volume: 47,774 shs
• Market Capitalization: N/A
• P/E Ratio: 0.42
• Dividend Yield: 137.99%
• Price Target: N/A
• Consensus Rating: Reduce

Kyowa Kirin Stock Analysis - MarketRank™

Kyowa Kirin scored higher than 10% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Reduce

Consensus Rating

Kyowa Kirin has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Kyowa Kirin has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Kyowa Kirin is 0.42, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.81.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kyowa Kirin is 0.42, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.77.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Kyowa Kirin has a short interest ratio ("days to cover") of 446.5, which indicates bearish sentiment.

Change versus previous month

Short interest in Kyowa Kirin has recently decreased by 2.25%, indicating that investor sentiment is improving.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Kyowa Kirin pays a meaningful dividend of 1.56%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Kyowa Kirin does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Kyowa Kirin is 58.08%. This payout ratio is at a healthy, sustainable level, below 75%.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Kyowa Kirin insiders have not sold or bought any company stock.

Percentage Held by Institutions

10.28% of the stock of Kyowa Kirin is held by institutions.

Company Calendar

• Today: 9/28/2026
• Next Earnings (Estimated): 10/29/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:KYKOF
• CIK: N/A
• Web: www.kyowakirin.com
• Phone: (135) 205-7200
• Fax: N/A
• Employees: 5,974
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 0.42
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A